India has ordered its pharmaceutical companies to meet new manufacturing standards this year after a string of deaths reported overseas linked to Indian-made drugs since 2022.
In 2022, more than 60 children, most under five years of age, died as a result of acute kidney injuries which were linked to cough syrups made in India.
Then last year, the manufacturer of over two dozen varieties of eyedrops was subject to a US safety warning officially recalling the products.
The Indian health ministry’s inspections of 162 drug factories since December 2022 found an “absence of testing of incoming raw materials”.
To ensure safety of pharma products made in the country, India has ordered its drug-makers to follow new standards.
Drug manufacturers must also retain a sufficient quantity of the samples of intermediate and final products to allow repeated testing or verification of a batch, the Indian government said.
The original article contains 401 words, the summary contains 147 words. Saved 63%. I’m a bot and I’m open source!